Literature DB >> 26645222

Non-Infectious Uveitis: Optimising the Therapeutic Response.

Archana Airody1, Greg Heath1, Susan Lightman2, Richard Gale3.   

Abstract

Non-infectious uveitis mainly affects the working-age population and can contribute to significant social and economic burden. It comprises a heterogeneous group of conditions with varied aetiology. Precise and early diagnosis, excluding masquerade syndromes, is the key to early therapeutic intervention. Treatment should be appropriately selected according to the anatomical sites of inflammation, the diagnosis and known prognosis, and whether there is a systemic inflammatory drive. Corticosteroids in the form of local or systemic therapy form the mainstay of treatment; however, due to unacceptable side effects, the need for long-term use or suboptimal response, corticosteroid-sparing medications may need to be considered early on in the management of non-infectious uveitis. With newer insights into the immunopathology of uveitis and the availability of biologic agents, treatment can be tailored according to individual needs. Many patients have systemic involvement, and hence a multidisciplinary approach is often required to achieve the best outcome in an individual. Patient involvement in the management of non-infectious uveitis, ensuring compliance, and continual monitoring of both the treatment and therapeutic response are the key to achieving optimal outcomes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26645222     DOI: 10.1007/s40265-015-0502-y

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

Review 2.  Recent developments in the treatment of uveitis: an update.

Authors:  Fiona Lyon; Richard P Gale; Susan Lightman
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

3.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Authors:  Andrew D Dick; Ilknur Tugal-Tutkun; Stephen Foster; Manfred Zierhut; S H Melissa Liew; Vladimir Bezlyak; Sofia Androudi
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

4.  Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Authors:  Grace Levy-Clarke; Douglas A Jabs; Russell W Read; James T Rosenbaum; Albert Vitale; Russell N Van Gelder
Journal:  Ophthalmology       Date:  2013-12-17       Impact factor: 12.079

5.  International Uveitis Study Group (IUSG): clinical classification of uveitis.

Authors:  Jean Deschenes; Philip I Murray; Narsing A Rao; Robert B Nussenblatt
Journal:  Ocul Immunol Inflamm       Date:  2008 Jan-Feb       Impact factor: 3.070

6.  Correlation between visual function and visual ability in patients with uveitis.

Authors:  A M Gardiner; R A Armstrong; M C M Dunne; P I Murray
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

Review 7.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

8.  Dexamethasone intravitreal implant for the treatment of noninfectious uveitis.

Authors:  Rebecca S Hunter; Ann-Marie Lobo
Journal:  Clin Ophthalmol       Date:  2011-11-11

9.  Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis.

Authors:  Lavnish Joshi; Lazha Talat; Satish Yaganti; Sartaj Sandhu; Simon R J Taylor; Denis Wakefield; Peter McCluskey; Susan Lightman
Journal:  Ophthalmology       Date:  2014-01-13       Impact factor: 12.079

10.  Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease.

Authors:  Imran J Khan; Robert J Barry; Kwesi N Amissah-Arthur; David Carruthers; Srinivasa Rao Elamanchi; Deva Situnayake; Philip I Murray; Alastair K Denniston; Saaeha Rauz
Journal:  Br J Ophthalmol       Date:  2012-11-30       Impact factor: 4.638

View more
  9 in total

1.  Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.

Authors:  Alejandro Gómez-Gómez; Alfredo Madrid-Garcia; Lara Borrego-Sanz; Paula Álvarez-Hernández; Pedro Arriola-Villalobos; Inés Pérez-Sancristobal; José M Benítez Del Castillo; Rosalía Mendez-Fernandez; Esperanza Pato-Cour; David Díaz-Valle; Luis Rodriguez-Rodriguez
Journal:  Ophthalmol Ther       Date:  2022-10-20

2.  Development and Characterization of PEGylated Fatty Acid-Block-Poly(ε-caprolactone) Novel Block Copolymers and Their Self-Assembled Nanostructures for Ocular Delivery of Cyclosporine A.

Authors:  Ziyad Binkhathlan; Abdullah H Alomrani; Olsi Hoxha; Raisuddin Ali; Mohd Abul Kalam; Aws Alshamsan
Journal:  Polymers (Basel)       Date:  2022-04-19       Impact factor: 4.967

3.  Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.

Authors:  Mayara Rodrigues Brandão De Paiva; Nayara Almeida Lage; Maria Carolina Andrade Guerra; Marcos Paulo Gomes Mol; Marcela Coelho Silva Ribeiro; Gustavo De Oliveira Fulgêncio; Dawidson A Gomes; Isabela Da Costa César; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  Doc Ophthalmol       Date:  2018-11-19       Impact factor: 2.379

4.  Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.

Authors:  Kongnara Papangkorn; Eri Prendergast; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2017-10-12       Impact factor: 2.671

Review 5.  A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.

Authors:  Lei Zhu; Binyao Chen; Wenru Su
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 6.  Management of chronic ocular sarcoidosis: challenges and solutions.

Authors:  Artemis Matsou; Konstantinos T Tsaousis
Journal:  Clin Ophthalmol       Date:  2018-03-19

7.  Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.

Authors:  Shuai Ming; Kunpeng Xie; Huijuan He; Ya Li; Bo Lei
Journal:  Drug Des Devel Ther       Date:  2018-07-04       Impact factor: 4.162

8.  Assessment of Anterior Uveitis Through Anterior-Segment Optical Coherence Tomography and Artificial Intelligence-Based Image Analyses.

Authors:  Martin Arman Sorkhabi; Ivan O Potapenko; Tomas Ilginis; Mark Alberti; Javier Cabrerizo
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.283

9.  Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases.

Authors:  Martina Bonacini; Alessandra Soriano; Luca Cimino; Luca De Simone; Elena Bolletta; Fabrizio Gozzi; Francesco Muratore; Maria Nicastro; Lucia Belloni; Alessandro Zerbini; Luigi Fontana; Carlo Salvarani; Stefania Croci
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.